ArticleScientific reports2026
Cardiac-specific mortality prediction in adolescents and young adults with classical hodgkin lymphoma: a nomogram development and validation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
As survival for classical Hodgkin lymphoma (cHL) improves, cardiac disease is a leading cause of non-relapse mortality, yet the risk of cardiac-specific mortality (CSM) in adolescents and young adults (AYAs) is unclear. This study developed and validated a nomogram to predict CSM for AYAs with cHL using data from the SEER database, with a training cohort of 7,475 patients for model development and a validation cohort of 3,205 patients for internal validation. A Fine-Gray competing risk model was used, with the cumulative incidence of CSM surpassing that of cHL over time. Analysis identified Black race, male sex, older age, earlier diagnosis year, and radiotherapy as significant risk factors for CSM. The resulting nomogram estimates the 15- and 25-year risks of CSM using age, race, sex, diagnosis year, Ann Arbor stage, and radiotherapy. Validation demonstrated strong discriminatory ability via ROC curves, with calibration plots and decision curve analysis confirming its accuracy and clinical utility. This nomogram is a useful tool for predicting CSM in the AYA population and may aid physicians in managing clinical risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.